IFNA1 and cancer: Nevertheless, type I and type II IFN signaling and sensing pathways could be hijacked by malignant cells to facilitate their survival and escape immunosurveillance [1, 5, 6], which eliminates effective response to ICB and even induces cancer hyper-progression during immunotherapy [7].